MSD Finland Oy
Welcome,         Profile    Billing    Logout  
 20 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Eren, Alev
KEYNOTE-057, NCT02625961 / 2014-004026-17: Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/)

Checkmark From KEYNOTE-057 trial in NMIBC
Jun 2021 - Jun 2021: From KEYNOTE-057 trial in NMIBC
Checkmark KEYNOTE-057 trial in NMIBC
Dec 2018 - Dec 2018: KEYNOTE-057 trial in NMIBC
Recruiting
2
320
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA, Pembrolizumab/vibostolimab coformulation, MK-7684A, Favezelimab/pembrolizumab coformulation, MK-4280A
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck &
Bladder Cancer
08/26
08/30
KEYNOTE-365, NCT02861573 / 2016-002312-41: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/)

Checkmark 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Sep 2022 - Sep 2022: 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Recruiting
1/2
1200
Europe, Canada, US, RoW
Pembrolizumab 200 mg, KEYTRUDA®, MK-3475, Olaparib 400 mg, LYNPARZA®, MK-7339, Docetaxel 75 mg/m^2, TAXOTERE®, Prednisone 5 mg, Enzalutamide 160 mg, XTANDI®, Dexamethasone 8 mg, Olaparib 300 mg, Abiraterone acetate 1000 mg, ZYTIGA®, Lenvatinib, LENVIMA®, MK-7902, Pembrolizumab/Vibostolimab coformulation, MK-7684A, Carboplatin, PARAPLATIN®, Etoposide, TOPOSAR™, Belzutifan 120mg, WELIREG™
Merck Sharp & Dohme LLC
Metastatic Castration-Resistant Prostate Cancer
10/27
10/27
Gefen, Eran
KEYNOTE-365, NCT02861573 / 2016-002312-41: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/)

Checkmark 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Sep 2022 - Sep 2022: 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Recruiting
1/2
1200
Europe, Canada, US, RoW
Pembrolizumab 200 mg, KEYTRUDA®, MK-3475, Olaparib 400 mg, LYNPARZA®, MK-7339, Docetaxel 75 mg/m^2, TAXOTERE®, Prednisone 5 mg, Enzalutamide 160 mg, XTANDI®, Dexamethasone 8 mg, Olaparib 300 mg, Abiraterone acetate 1000 mg, ZYTIGA®, Lenvatinib, LENVIMA®, MK-7902, Pembrolizumab/Vibostolimab coformulation, MK-7684A, Carboplatin, PARAPLATIN®, Etoposide, TOPOSAR™, Belzutifan 120mg, WELIREG™
Merck Sharp & Dohme LLC
Metastatic Castration-Resistant Prostate Cancer
10/27
10/27
Pasternack, Michael
KEYNOTE-057, NCT02625961 / 2014-004026-17: Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/)

Checkmark From KEYNOTE-057 trial in NMIBC
Jun 2021 - Jun 2021: From KEYNOTE-057 trial in NMIBC
Checkmark KEYNOTE-057 trial in NMIBC
Dec 2018 - Dec 2018: KEYNOTE-057 trial in NMIBC
Recruiting
2
320
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA, Pembrolizumab/vibostolimab coformulation, MK-7684A, Favezelimab/pembrolizumab coformulation, MK-4280A
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck &
Bladder Cancer
08/26
08/30
KEYNOTE-365, NCT02861573 / 2016-002312-41: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/)

Checkmark 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Sep 2022 - Sep 2022: 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Recruiting
1/2
1200
Europe, Canada, US, RoW
Pembrolizumab 200 mg, KEYTRUDA®, MK-3475, Olaparib 400 mg, LYNPARZA®, MK-7339, Docetaxel 75 mg/m^2, TAXOTERE®, Prednisone 5 mg, Enzalutamide 160 mg, XTANDI®, Dexamethasone 8 mg, Olaparib 300 mg, Abiraterone acetate 1000 mg, ZYTIGA®, Lenvatinib, LENVIMA®, MK-7902, Pembrolizumab/Vibostolimab coformulation, MK-7684A, Carboplatin, PARAPLATIN®, Etoposide, TOPOSAR™, Belzutifan 120mg, WELIREG™
Merck Sharp & Dohme LLC
Metastatic Castration-Resistant Prostate Cancer
10/27
10/27
Elomaa, Kaisa
No trials found

Download Options